ReviewInternational journal of molecular sciences2012
Biochemistry of bacterial multidrug efflux pumps.
Review in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Bioprospecting of cultivable actinobacteria from tropical peat swamp forest soil reveals Streptomyces with potent antimicrobial activity.Antonie van Leeuwenhoek · 2026Article
- A review of research progress on periplasmic adaptor proteins in bacterial tripartite pumps.Frontiers in microbiology · 2026Review
- Investigation of Phytol as an Inhibitor of the Efflux Pump (QacA/B) in Staphylococcus aureus: in silico and in vitro Studies.Pharmaceutical research · 2026Article
- Identification of genetic mutations conferring tedizolid resistance in MRSA mutants.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- The burden of group AiScience · 2025Review
- Quantum biochemical analysis of the TtgR regulator and effectors.Scientific reports · 2024Article
- Efflux-mediated Multidrug Resistance in Critical Gram-negative Bacteria and Natural Efflux Pump Inhibitors.Current drug research reviews · 2024Review
- Multidrug Efflux System-mediated resistance in Staphylococcus aureus under a One Health approach.World journal of microbiology & biotechnology · 2023Article
- Review
- Genomic and phenotypic profiling of Staphylococcus aureus isolates from bovine mastitis for antibiotic resistance and intestinal infectivity.BMC microbiology · 2023Article
- Efflux Pump (QacA, QacB, and QacC) and β-Lactamase Inhibitors? An Evaluation of 1,8-Naphthyridines againstMolecules (Basel, Switzerland) · 2023Article
- Membrane Efflux Pumps of PathogenicMicroorganisms · 2022Review
- Bacterial Resistance to Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2021Review
- Lessons and Considerations for the Creation of Universal Primers Targeting Non-Conserved, Horizontally Mobile Genes.Applied and environmental microbiology · 2021Article
- Efficacy and Mechanisms of Flavonoids against the Emerging Opportunistic Nontuberculous Mycobacteria.Antibiotics (Basel, Switzerland) · 2020Review
- Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria.Microorganisms · 2020Review
- Functional and Structural Roles of the Major Facilitator Superfamily Bacterial Multidrug Efflux Pumps.Microorganisms · 2020Review
- Insights Into the Resistome of Bovine Clinical Mastitis Microbiome, a Key Factor in Disease Complication.Frontiers in microbiology · 2020Article
- Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?Clinical microbiology reviews · 2018Review
- The prototypical proton-coupled oligopeptide transporter YdgR fromThe Journal of biological chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Bacterial pathogens that are multi-drug resistant compromise the effectiveness of treatment when they are the causative agents of infectious disease. These multi-drug resistance mechanisms allow bacteria to survive in the presence of clinically useful antimicrobial agents, thus reducing the efficacy of chemotherapy towards infectious disease. Importantly, active multi-drug efflux is a major mechanism for bacterial pathogen drug resistance. Therefore, because of their overwhelming presence in bacterial pathogens, these active multi-drug efflux mechanisms remain a major area of intense study, so that ultimately measures may be discovered to inhibit these active multi-drug efflux pumps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.